首页>投融资
ONL Therapeutics
D轮
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.In March 2023, ONL Therapeutics LLC closed on the first tranche of a $15 million Series C Preferred Stock financing round.In December 2020 ,ONL Therapeutics announced that it closed on $46.9 million in a Series B Preferred Stock financing round. In January 2022, ONL Therapeutics Inc closed on its second tranche of Series B financing raising $46.9 million.In August 2019, the company raised US $3 million in a convertible note financing.In May 2017, the company closed a US $4.25 million Series A round of fundraising
基本信息
-
公司全称ONL Therapeutics Inc
-
类型眼科药物研发商
-
产业领域生物药、药品研发/制造
-
公司人数15~50人
-
地址524 S. Main St,Suite 110 ANN ARBOR MICHIGAN 48104; US; Telephone: +17349988339;
-
联系电话（734）998.8339
-
邮箱info@onltherapeutics.com
-
成立时间2011-01-01
投融资
-
2024-09-13D轮6500万美元Johnson & Johnson InnovationVisionary Venture FundBios Partners诺华
-
2023-03-08C轮1500万美元Bios PartnersVisionary Venture FundAlpine VisionaryMayewell CapitalJohnson & Johnson Innovation凯泰资本PSQ CapitalMichigan CapitalExSight VenturesCapital Community AngelsMINTS
-
2020-12-22B轮4690万美元Capital Community AngelsMichigan CapitalMINTSExSight VenturesInFocus Capital PartnersPSQ Capital凯泰资本强生（中国）Bios Partners
-
2019-08-22债权融资300万美元Invest MichiganCCAIInFocus Capital PartnersBRCC
-
2017-05-17A轮425万美元诺华
-
2017-03-21捐赠/众筹/授予100万美元National Institutes of Health
-
2014-11-12捐赠/众筹/授予137万美元National Eye Institute
- 加载更多
相关投融资企业
收并购
Chengdu Boaovax Biotechnology, founded in November 2015, is focused on R & D of vaccines
上市后再融资
宜明昂科2015年6月成立于上海张江，自创立以来，坚持全球创新和自主研发，围绕着固有免疫和获得性免疫多个潜力靶点做出了一系列产品布局。迄今为止，已在中国获得9个临床批件，在美国获得2个临床批件。另外，IMM01与PD-1针对多个实体瘤适应症的联合用药临床试验申请已获药监局受理。现有临床数据表明，无论安全性还是有效性，IMM01在全球范围靶向CD47的分子中表现亮眼，有很大希望成为同类最优（Best-In-Class）产品。同时，公司围绕CD47靶点布局的一系列联合用药和双抗，能够更大的拓展CD47靶点实体瘤适应症潜力。CD47之余，宜明昂科围绕固有免疫和获得性免疫进一步拓展布局了后续两个具有全球竞争力的创新潜力靶点，固有免疫和获得性免疫靶点形成强大协同，成为推动公司不断创新发展的强有力的引擎。
D轮
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.In March 2023, ONL Therapeutics LLC closed on the first tranche of a $15 million Series C Preferred Stock financing round.In December 2020 ,ONL Therapeutics announced that it closed on $46.9 million in a Series B Preferred Stock financing round. In January 2022, ONL Therapeutics Inc closed on its second tranche of Series B financing raising $46.9 million.In August 2019, the company raised US $3 million in a convertible note financing.In May 2017, the company closed a US $4.25 million Series A round of fundraising
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息